Coronary artery disease remains the leading cause of mortality in most industrialized countries, although age-standardized mortality related to coronary artery disease (CAD) has decreased by more than 40% during the last two decades. Coronary atherosclerosis may cause angina pectoris, myocardial infarction, heart failure, arrhythmia, and sudden death. Medical management of atherosclerosis and its manifestation aims at retardation of progression of plaque formation, prevention of plaque rupture, and subsequent events and treatment of symptoms, when these occur as well as treatment of the sequelae of the disease. Revascularization by either percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG) is performed as treatment of flow-limiting coronary stenosis to reduce myocardial ischaemia. In high-risk patients with acute coronary syndromes (ACS), a routine invasive strategy with revascularization in most patients provides the best outcome with a significant reduction in death and myocardial infarction compared with an initial conservative strategy. Conversely, the benefit of revascularization among patients with chronic stable CAD has been called into question. This review will provide information that revascularization exerts favourable effects on symptoms, quality of life, exercise capacity, and survival, particularly in those with extensive CAD and documented moderate-to-severe ischaemia. Accordingly, CABG and PCI should be considered a valuable adjunct rather than an alternative to medical therapy.
Introduction
Coronary artery disease (CAD) remains the leading cause of mortality in most industrialized countries, although age-standardized mortality related to CAD has decreased by more than 40% during the last two decades. 1, 2 Half of this decline resulted from prevention and reduction in major risk factors, whereas the other half has been attributed to medical treatment and revascularization. 3 Coronary artery disease is the result of atherosclerosis, a progressive disorder of the vessel walls, with formation of plaques throughout the arterial system. 4 Vascular inflammation may lead to disruption of the endothelium overlying a plaque and cause subsequent intravascular thrombosis. 5, 6 Symptoms related to atherosclerosis vary depending on the location and degree of stenosis of the vessels and the occurrence, site, and severity of plaque disruption. Coronary atherosclerosis may thus be asymptomatic or cause angina pectoris, myocardial infarction (MI), heart failure, arrhythmias, and sudden death. 4 Medical management of atherosclerosis and its manifestation aims at retardation of progression of plaque formation, prevention of plaque rupture, and subsequent events and treatment of symptoms, when these occur as well as treatment of the sequelae of the disease. Revascularization by either percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG) is performed as treatment of flow-limiting coronary stenosis to reduce myocardial ischaemia and its manifestations.
In high-risk patients with acute coronary syndromes (ACS, with or without ST-segment elevation) a routine invasive strategy with revascularization in most patients provides the best outcome with a significant reduction in death and MI compared with an initial conservative strategy. 7 -10 Conversely, the benefit of revascularization among patients with chronic stable CAD has been called into question ( Table 1) . 11 -13 In particular, the appropriateness of PCI has been challenged because many patients undergoing PCI lack documentation of ischaemia by non-invasive testing prior to the procedure, 14 the incremental cost, 15 and an alleged lack of survival benefit. 12, 16, 17 Therefore, in this review we discuss the indications for Pathophysiology of stable coronary artery disease Assessment of the severity of coronary artery disease Advanced age, left-ventricular function (ejection fraction), and the extent and severity of coronary stenosis as assessed at the time of diagnostic coronary angiography and the presence or absence of more extensive atherosclerosis in other vascular beds are the most important prognostic factors in patients with established CAD.
Several risk-scores, based on clinical factors have been proposed to predict the risk for MI or death in patients with stable CAD. 26 Also a simple classification into single-, double-, triple-, and left main CAD is clinically useful and is a major prognostic indicator during long-term follow-up of angiography studies. 27, 28 Additional prognostic information is provided by the severity of coronary artery obstruction and its location, which are combined in the CAD jeopardy score, the Duke prognostic CAD index, and more recently the SYNTAX score. 29 -32 Taken together these data provide a gradient of risk with more extensive and severe CAD portending worse prognosis.
Assessment of lesion severity is mostly based on coronary angiography, while the structure of the vessel wall and plaque morphology may be studied with intravascular ultrasound or optical coherence tomography. 33, 34 Obstructive coronary artery lesions progressively restrict the ability to increase blood flow in response to changing metabolic demands and lead to myocardial ischaemia at rest or during exercise. 35 Generally, compensatory vasodilatory mechanisms are exhausted with lesions exceeding 80% of lumen diameter, 36 while dysfunction of the endothelium or spasm may aggravate a stenosis caused by a coronary plaque ( Figure 1) . 37, 38 The advent of sensor-tipped guidewires allows for physiological determination of lesion significance by measuring fractional flow reserve (FFR) during pharmacologically induced maximal hyperaemia. 39 A threshold of FFR ,80% has been correlated with ischaemia as detected by nuclear imaging procedures or stress echocardiography and constitutes a criterion for revascularization. 40 
Manifestations of chronic myocardial ischaemia
Myocardial ischaemia typically elicits a cascade of events characterized by diastolic and systolic ventricular dysfunction with regional wall motion abnormalities, ST-segment changes, and the development of ischaemic pain (angina pectoris). Prolonged myocardial ischaemia causes myocardial cell death. 41 Chronic CAD is by far the commonest cause of heart failure. 42 Chronic stable CAD, %  53  49  42  45  Unstable angina/non-ST elevation MI, %  30  29  36  39 ST-elevation MI, % 16 22 21 16 Approximately half of procedures are performed in patients with acute coronary syndromes, whereas the other half of interventions are in the setting of chronic stable coronary artery disease. CAD, coronary artery disease; MI, myocardial infarction.
cardiomyopathy CAD is frequently found at autopsy. 43 Chronic or repetitive reduction of myocardial perfusion owing to severely obstructed coronary arteries or collateralized total occlusions may result in non-contractile but viable myocardium, which recovers after coronary revascularization, a process referred to as 'hibernation'. 44, 45 In two-thirds of patients with stable CAD and left-ventricular dysfunction a decline in left-ventricular ejection fraction was observed during the waiting period prior to CABG, which resolved at least in part following revascularization. 46 Plaque rupture and erosion with thrombotic complications are a frequent cause of MI and sudden death. 6, 47 However, ruptured plaques may go clinically undetected and heal ( Figure 2) . 48 This was confirmed in recent clinical studies using in vivo imaging which identified superimposed layers of necrotic areas covered by fibrosis. 49 Post-mortem examination of patients who died of acute MI showed severe underlying coronary artery narrowing with a mean diameter stenosis of 91% (range 67 -99%) at sites of plaque rupture. 50 In contrast, MI in patients most often occurs by plaque rupture and thrombosis at a 'non significant' lesion, i.e. a plaque with ,50% coronary stenosis at angiography. 5, 6, 47 While non-obstructive atherosclerotic lesions are by far more prevalent in the general population than severe lesions and therefore frequently encountered in ACS patients, high-grade coronary artery stenoses are hazardous and play an ominous role in sudden death and fatal MI. 48, 51 These observations support the concept of revascularization by PCI or CABG of coronary lesions causing myocardial ischaemia whether or not angina is present, provided that such ischaemia is documented in that patient.
Medical treatment of coronary artery disease and angina pectoris
In addition to a healthy lifestyle, drug therapy aims at retardation of progression of atherosclerosis, or perhaps even its regression, and at prevention of cardiovascular events such as death, MI, or stroke. 18, 52 Preventive treatment includes aspirin, statins, ACE-inhibitors, angiotensin receptor blockers, and b blockers in patients after MI 53 and patients with heart failure. In addition, clopidogrel, prasugrel, and ticagrelor reduce recurrent events in the first year after an ACS. 54 -56 It should be appreciated that these drugs, apart from b blockers, do not reduce angina pectoris or ischaemia when present.
The numbers needed to treat with these drugs depend on the risk for future events of a specific patient group. Patients with stable CAD included in the recent ACTION or EUROPA trials, who already received different preventive drugs, had an annual risk of cardiovascular death or MI of about 2.5%. 24 -26 To avoid one such event, about 175 patients should be treated during 1 year with aspirin (relative risk reduction 23%), about 120 patients with a 'standard dose' statin (RRR 30%), 200 with an ACE inhibitor or AT2 receptor blocker (RRR 20%), 200 patients with clopidogrel in the first year after ACS (RRR 20%), and 240 with high dose statin (RRR 15% when compared with lower statin dose). In patients at higher risk, the numbers needed to treat are obviously lower, and treatment is more cost-effective.
Immediate relief of angina can be provided by nitroglycerine, isosorbide mononitrate, or chewing a nifedipine capsule. Patients may also be instructed to use these short acting drugs prior to exercise, in order to reduce the likelihood of subsequent angina. In symptomatic patients the frequency of episodes of angina and nitroglycerine consumption can be reduced by long acting nitrates, b blockers, and calcium antagonists. 52 These well-established agents improve exercise tolerance during a stress test, and reduce the need for revascularization by PCI or CABG. 23 Recently two new classes of drugs have been introduced which have similar effects as the established agents, albeit through completely different modes of action.
These drugs have not yet been evaluated by the ESC guideline committee. Ivabradine reduces heart rate (sinus rhythm) at rest as well as during exercise by inhibition of the If current in the sino-atrial node, without any effect on blood pressure, intracardiac conduction, QT interval, or myocardial contractility. In a series of clinical trials ivabradine reduced nitroglycerine consumption and improved exercise tolerance during a stress test when compared with placebo in patients with different background therapies. 57 -59 In comparative studies ivabradine was equally effective as atenolol or amlodipine mono-therapy. 58 In a large clinical trial in patients with leftventricular dysfunction, ivabradine was safe, even when given in combination with b blockers and reduced the number of revascularization procedures during follow-up, in particular in patients with a resting heart rate above 70 b.p.m., but it did not reduce the rates of cardiovascular death of MI. 60 Up to 25% of patients receiving ivabradine experience flashes in the eye or other mild visual symptoms which disappear at continuation of therapy and rarely are a reason to discontinue the drug. 60 Ranolazine selectively inhibits the late sodium influx in the myocardium, which is increased during myocardial ischaemia. 61 Thus ranolazine attenuates the ischaemic abnormalities of ventricular repolarization and the resulting reduced contractility. In clinical trials ranolazine improves exercise tolerance and reduces the frequency of angina episodes compared with placebo in patients with angina pectoris. 61 Side effects include nausea, dizziness, and asthenia. Ranolazine causes some prolongation of the QT interval; however, no significant arrhythmias have been reported. In a large clinical trial in patients after an ACS no significant reduction in subsequent death or MI was observed. 62 
Revascularization in stable coronary artery disease
Revascularization, relief of ischaemia, and prognosis
The principal goal of revascularization is the relief of ischaemia to improve quality of life and exercise capacity, to reduce the amount of anti-angina drugs, and ultimately improve prognosis on top of the beneficial effects of medical treatment. Symptomatic and asymptomatic ischaemia are of prognostic importance in patients with CAD particularly when occurring at low workload. 63, 64 Revascularization, by eliminating the target lesion (PCI) or bypassing the narrowed epicardial vessel (CABG), more effectively relieves myocardial ischaemia than medical treatment alone ( Table 2) . For example, in the randomized Asymptomatic Cardiac Ischemia Pilot (ACIP) study, 57% of patients treated with revascularization were free of ischaemia at 1 year compared with 31 and 36% in the ischaemia-guided and angina-guided strategies, respectively (P , 0.0001). Furthermore, at 2 years follow-up, the risk of death and MI was significantly lower among patients undergoing revascularization (4.7%) compared with those receiving ischaemia-guided (8.8%) or angina-guided medical treatment (12.1%, P , 0.04). 65 Similarly, patients with silent ischaemia after recent MI enrolled into the randomized SWISSI II trial showed lower rates of ischaemia when allocated to PCI (12%) than medical treatment (29%, P ¼ 0.03), a beneficial effect accompanied by improved left-ventricular ejection fraction (57 vs. 49%, P , 0.001) and an absolute reduction in clinical events (cardiac death, MI, and revascularization) of 6.3% per year in favour of PCI. 66 Along the same line, patients with angina or exercise-induced ischaemia early after MI had a better prognosis after revascularization than with medical therapy alone in the DANAMI study. 67 In the myocardial perfusion substudy of COURAGE, PCI compared with medical treatment showed a greater absolute reduction in myocardial ischaemia (22.7 vs. 20.5%, P , 0.0001), and more patients exhibited a relevant reduction in ischaemia (33 vs. 19%, P ¼ 0.0004), particularly among those with moderate to severe ischaemia (78 vs. 52%, P ¼ 0.007). 68 Again, there was a graded relationship between reduction of ischaemia and subsequent risk of death or MI with improved event-free survival in patients with significant reduction of ischaemia. 68 Various observational studies have addressed the impact of revascularization on prognosis. A myocardial perfusion study of Stable CAD: drugs vs. revascularization 10 627 patients without prior CAD showed an increasing survival benefit of revascularization over medical treatment in patients with moderate to severe ischaemia, whereas no such benefit was apparent in patients with only mild or absence of ischaemia (Figure 3 ). 69 The effect of revascularization on prognosis has also been investigated in a meta-analysis of 24 studies encompassing 3088 patients with left-ventricular dysfunction (mean LVEF ¼ 32 + 8%) who underwent assessment of viability by means of thallium perfusion imaging, F-18 fluorodeoxy glucose metabolic imaging, or Dobutamine stress echocardiography and were followed for a mean of 25 months. 70 In patients with viability, revascularization was associated with an 80% reduction of risk-adjusted mortality compared with medical treatment (16%/year vs. 3%/year). This benefit was most apparent in patients with impaired left-ventricular function.
No benefit was observed in patients without viability at any level of left-ventricular function. The Alberta Provincial Project for Outcome Assessment in CAD (APPROACH) assessed survival according to treatment allocation in 11 661 patients with multivessel CAD undergoing coronary angiography. 71 Risk-adjusted mortality was significantly lower with both CABG (HR ¼ 0.53, CI 0.46-0.61, P , 0.001) and PCI (HR ¼ 0.65, 95% CI 0.56 -0.74, P , 0.001) compared with medical treatment in the overall cohort as well as patients with three-vessel CAD, whereas CABG was superior to both PCI and medical treatment in the subset of patients with left main CAD.
At Duke University Medical Center, 18 481 patients undergoing coronary angiography between 1986 and 2000 underwent prospective evaluation of risk-adjusted mortality according to treatment assignment. 72 During long-term follow-up revascularization (CABG or PCI) provided a significant survival advantage over medical treatment in patients with low-, intermediate-, and highseverity CAD. The absolute survival advantage amounted to 8, 11, and 24 months of life during 15 years of follow-up comparing CABG with medical treatment. The treatment effect was similar for CABG and PCI in low-and intermediate severity CAD, but CABG prevailed over PCI in high-severity CAD. In the EUROPA study of over 12 000 patients with stable CAD, a risk model was developed. Risk factors for mortality during 4.2 years follow-up included elderly age, a history of MI, stroke or peripheral vascular disease, male gender and diabetes, while previous PCI or CABG was associated with a reduced risk. 26 In summary, revascularization is associated with improved clinical outcome in patients with documented moderate-to-severe myocardial ischaemia or viable myocardium, in particular when associated with left-ventricular dysfunction and multivessel CAD.
Randomized trials comparing revascularization with medical treatment
To date 30 randomized trials have compared medical treatment with revascularization by means of PCI or CABG in patients with chronic stable CAD ( Table 3) . 66,67,73 -104 The number of patients included into these trials ranged from 44 88 to 2368. 104 Coronary artery bypass surgery was applied as revascularization therapy in 13 trials, of which 6 were performed more than 2 decades ago using predominantly saphenous vein grafts. Balloon angioplasty alone was used in eight studies, whereas subsequent trials reported the use of stents in 9-100% of procedures. Drug-eluting stent implantation was negligible except for BARI-2D (35% of patients). Several trials failed to specify the implemented medical treatment. The majority of studies included predominantly male patients who were relatively young (with the exception of TIME), had preserved left-ventricular function and had not undergone previous revascularization by CABG or PCI. One study enrolled exclusively diabetic patients (BARI-2D). 104 Patients were highly selected as randomization was performed following delineation of coronary anatomy by angiography in the vast majority of studies. By design all trials compared treatment strategies (intention-to-treat, routine revascularization vs. initial medical treatment) allowing subsequent revascularization when patients deteriorated on medical therapy. Such 'cross-over' from medical treatment to revascularization was observed in up to half of patients during follow-up. Accordingly the proportion of patients without revascularization progressively diminished during follow-up, potentially blunting differences between the two strategies.
The largest study comparing PCI with current medical treatment (COURAGE) enrolled 2287 (6.4%) of 35 539 patients undergoing eligibility assessment during a 5 year period. 102 Half of patients had minimal or no symptoms of angina and the extent of ischaemia as assessed by nuclear imaging prior to treatment in a subset of patients was not severe. The rate of death was similar in the PCI (7.6%) and medical therapy group (8.3%, HR ¼ 0.87, 95% CI 0.65-1.16, P ¼ 0.38). Non-protocol revascularization procedures were less frequent among PCI patients (21 vs. 33%, HR ¼ 0.60, 95% CI 0.51-0.71) during follow-up.
The recently reported BARI-2D trial randomly assigned 2368 diabetic patients to medical treatment or revascularization, stratified according to choice of PCI (34%) or CABG (16%). Coronary revascularization was performed in 97% of patients in the revascularization and 42% of patients in the medical therapy group during follow-up ( Figure 4) . The use of drug-eluting stents (35%) was low as was the prescription of thienopyridines (21%). At 5 years, mortality did not differ between the medical therapy (13.5%) and the revascularization group (13.2%) in either the CABG or PCI stratum. Major adverse cardiac events (death, MI, or stroke) were fewer among patients allocated to revascularization by CABG (20.9%) than those treated medically (29.9%, P ¼ 0.01), whereas no difference was observed in the PCI stratum (23.4 vs. 20.8%, P ¼ 0.15).
In contrast, the TIME study, which randomly assigned 301 elderly patients (.75 years of age) to an invasive or medical strategy without baseline coronary angiography, reported no difference in mortality according to initial treatment allocation. Of note, during longer-term follow-up to 4 years survival was significantly lower in patients undergoing revascularization (80%) compared with those not being revascularized (61%, P ¼ 0.003) irrespective of the initial treatment assignment. 105 Since none of these studies was powered to detect a difference in mortality or subsequent MI, meta-analyses are required to assess the impact of revascularization on patient outcome. A meta-analysis of the first seven trials comparing CABG with medical therapy established a reduction in mortality in selected patients following CABG with the benefit being proportional to the number of diseased coronary arteries and the degree of myocardial ischaemia. 106 In contrast, early systematic reviews comparing PCI (mainly balloon angioplasty) with medical treatment in relatively small numbers of patients failed to show a difference in the risk of death or MI. 107 -109 More recently, however, a meta-analysis of 17 randomized trials compared medical treatment with PCI in 7513 patients with an average follow-up of 51 months. 110 Revascularization was performed in 92% of patients allocated to PCI (43% balloon angioplasty, 41% stents, 8% CABG), whereas 28% of patients allocated to medical treatment underwent revascularization early or during follow-up. At follow-up, the risk of overall mortality was significantly reduced by 20% in favour of PCI (OR ¼ 0.80, 95% CI 0.64-0.99) with no apparent heterogeneity across trials (I 2 ¼ 17%), whereas the risk of MI was similar among both groups (OR ¼ 0.90, 95% CI 0.66-1.23). Exclusion of four studies allowing both CABG and PCI as treatment option did not impact the results regarding all-cause mortality. The benefit of revascularization became more pronounced with follow-up periods beyond 5 years. A network meta-analysis, however, did not find a significant reduction in mortality or MI for balloon angioplasty (PTCA) compared with medical therapy, nor with bare-metal stents compared with PTCA or drug-eluting stents compared with bare-metal stents. The different results of these meta-analyses reflect differences in the analytic methodology and trial selection, but also illustrate that any mortality benefits of PCI are modest at best. 111 The most recent review compared medical treatment with surgical or percutaneous revascularization in 13 121 patients enrolled into 17 PCI, 6 CABG, and 5 trials using either revascularization strategy. 112 Consistent with the previous meta-analysis, which covered most of the same trials, mortality was lower after revascularization than in the medical therapy group (7.9 vs. 9.8%, OR ¼ 0.74, 95% CI 0.63 -0.88). These findings remained consistent following exclusion of studies in patients with recent MI (OR ¼ 0.77, 95% CI 0.65-0.91). The treatment effect appeared more pronounced in early studies comparing CABG with medical treatment (OR ¼ 0.62, 95% CI 0.50 -0.77) than in the more recent studies comparing PCI with medical treatment (OR ¼ 0.82, 95% CI 0.68-0.99). Furthermore, confidence intervals overlapped widely and an analysis of variance revealed no significant difference between the two revascularization strategies (P ¼ 0.33)( Figure 5 ). Again, there was no difference in the risk of MI between both groups.
Recently, FFR was compared with angiography for guiding PCI in a large-scale randomized trial with 1005 patients (FAME). 113 At 1 year, routine measurement of FFR to select lesions requiring PCI (FFR , 80%) was associated with lower rates of death or MI (7.3 vs. 11.1%, P ¼ 0.04) than PCI guided by angiography alone. Similarly, deferring revascularization in patients with non-significant lesions as determined by FFR appeared safe as shown during the 5 year follow-up Stable CAD: drugs vs. revascularization of the randomized DEFER study with similar rates of death or MI (,1%/year) among patients treated medically and those undergoing PCI. 40 These findings imply that part of the patients enrolled in previous trials were unlikely to benefit from PCI or CABG if they had no, or limited myocardial ischaemia and suggest that functional assessment of lesions (ischaemia or none) may help to identify those who benefit from revascularization.
Revascularization and quality of life
Compared with medical therapy, revascularization by PCI or CABG has been consistently shown to more effectively relieve angina, reduce the use of anti-angina drugs, improve exercise capacity and quality of life (Tables 4 and 5). 107, 114 In the RITA-2 and COURAGE studies angina frequency and quality of life were assessed systematically. 115 PCI relieved angina and improved selfassessed health status to a greater degree than medical therapy alone up to 24 months. This benefit from PCI was greatest among patients with severe and frequent angina, and one-third of patients in the medical therapy group subsequently underwent PCI for symptom relief during follow-up. Freedom from angina was 66% in the PCI group of COURAGE when compared with 81% in the PCI group of FAME, a difference which may be explained by the near exclusive use of drug-eluting stents, reducing the rate of restenosis, in the latter. 113 Indeed, a recent meta-analysis showed sequential reductions in repeat revascularization with bare-metal stents compared with balloon angioplasty (risk reduction 32%) and with drug-eluting stents compared with bare-metal stents (risk reduction 56%), which undoubtedly impact quality of life. 111 
The debate
The presentation and publication of the COURAGE study caused a heated debate, particularly among colleagues from the USA. 17, 116 The validity of COURAGE was called into question owing to the inclusion of only 6.4% of the screened population, the relatively high proportion of patients lost to follow-up, the inclusion of patients with little or no ischaemia, allocation of treatment only after coronary angiography excluding patients at increased risk, and question marks regarding the quality of revascularization procedures in various health care settings. Moreover, the study was judged to be underpowered due to lower than expected event rates despite protocol amendments allowing for more liberal 74 72 inclusion and extension of follow-up. The definition of periprocedural infarction with any increase of CK-MB was felt oversensitive without clear prognostic relevance and not adhering to recommendations of published guidelines thus disadvantaging the PCI group. 41 Finally, cross-over from medical treatment to subsequent revascularization was not considered an adverse event but said to camouflage potential differences in outcome between the two treatment regimens. Notwithstanding these limitations, COURAGE and other individual studies have failed to show any superiority of PCI in terms of ischaemic endpoints ( Table 3) .
Earlier trials comparing an initially invasive-or non-invasive strategy in stable CAD were relatively small and under powered, particularly when compared with studies which assess preventive treatment with drugs including several thousand of patients. 24, 55, 56, 117, 118 Yet the results of meta-analyses of revascularization trials have shown a consistent benefit in terms of survival for CABG and a modest survival benefit for PCI. 106, 110, 112 Moreover, the data from large observational studies support the notion of a graded survival benefit derived from both revascularization procedures. 71, 72 The debate elicited by COURAGE has called our attention to the fact that, apart from many patients who appropriately benefit from PCI and CABG, the indications for such procedures in other patients are less well defined. Revascularization is primarily directed against the elimination of myocardial ischaemia as well as symptoms of affected patients. Thus, treatment of coronary lesions without ischaemia or of patients without symptoms is not beneficial. Yet, about half of the patients undergoing elective PCI for stable angina in the UK 119 and in the USA 14 do not undergo a stress test to document ischaemia before the procedure. Worldwide, inappropriate revascularization procedures increase healthcare cost and use scarce hospital resources.
Conclusions
All patients with atherosclerosis, including patients with angina pectoris, benefit from life long drug therapy in addition to a healthy lifestyle. In addition coronary revascularization is appropriate at some time or several times during their lifespan, either for episodes of ACSs or for treatment of myocardial ischaemia. Optimal management of CAD, as presented in ESC guidelines 18, 52 and similar publications includes: (i) appropriate lifestyle, i.e. no smoking, a healthy diet, weight control, and regular exercise; (ii) detection and treatment of diseases and conditions which increase the risk of atherosclerosis, in particular hypertension, diabetes, and hypercholesterolaemia; (iii) drug therapy to lower LDL cholesterol (statins) in subjects at high risk for new or recurrent atherosclerosis events; (iv) additional preventive therapy with aspirin, other anti-thrombotic agents, ACE-inhibitors, and b blockers in patients with known atherosclerosis; (v) symptomatic treatment with nitrates, b blockers, calcium channel blockers, and other anti-angina drugs; and (vi) revascularization by PCI or CABG in selected patients.
Revascularization exerts favourable effects on symptoms, quality of life, exercise capacity, and survival, particularly in those with extensive CAD and documented moderate-to-severe ischaemia. Accordingly, CABG and PCI should be considered a valuable adjunct rather than an alternative to medical therapy. Of note, the benefits of revascularization are associated with a low peri-procedural risk and therefore justify their implementation for symptomatic as well as prognostic reasons. As with most other therapeutic interventions in medicine, the relief of symptoms remains a noble task of physicians caring for patients with stable CAD, particularly in today's executive society where only few would opt to accept angina symptoms impeding their otherwise active life style.
The debate should not be medical vs. revascularization therapy but rather which patients should be offered revascularization and when. The timing of revascularization requires careful consideration. Patients with no or mild symptoms and little ischaemia can safely be treated with medical treatment alone. Conversely, patients with moderate-to-severe symptoms and/or extensive ischaemia should be strongly considered for revascularization therapy. Non-invasive (MS-CT, perfusion scintigraphy, or PET-CT) or invasive (FFR) identification of lesions giving rise to ischaemia may further improve outcome in patients submitted to revascularization. Patients undergoing coronary angiography for symptomatic CAD with an anatomy amenable to PCI should be offered the possibility to undergo revascularization during the same session (ad hoc) as treatment options (medical treatment, CABG, and PCI) are known and can be discussed in advance, sparing yet another invasive procedure. Finally, patient preference must be carefully weighed in the overall treatment selection.
We call upon our colleagues to review their practice and to comply with the recommendations for optimal medical management of all patients with angina and stable CAD as well as optimal use of PCI and CABG in appropriately selected patients. Stable CAD: drugs vs. revascularization
